Drug Type Antibody drug conjugate (ADC) |
Synonyms MK 2140, MK-2140, VLS-101 |
Target |
Mechanism ROR1 antagonists(Inactive tyrosine-protein kinase transmembrane receptor ROR1 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
Molecular FormulaC39H67N5O7 |
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N |
CAS Registry474645-27-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diffuse Large B-Cell Lymphoma | Phase 3 | US | 14 Jan 2022 | |
Diffuse Large B-Cell Lymphoma | Phase 3 | CA | 14 Jan 2022 | |
Diffuse Large B-Cell Lymphoma | Phase 3 | FR | 14 Jan 2022 | |
Diffuse Large B-Cell Lymphoma | Phase 3 | IL | 14 Jan 2022 | |
Diffuse Large B-Cell Lymphoma | Phase 3 | IT | 14 Jan 2022 | |
Diffuse Large B-Cell Lymphoma | Phase 3 | PL | 14 Jan 2022 | |
Diffuse Large B-Cell Lymphoma | Phase 3 | KR | 14 Jan 2022 | |
Diffuse Large B-Cell Lymphoma | Phase 3 | TH | 14 Jan 2022 | |
Diffuse Large B-Cell Lymphoma | Phase 3 | TR | 14 Jan 2022 | |
Diffuse Large B-Cell Lymphoma | Phase 3 | GB | 14 Jan 2022 |
Phase 2 | 98 | kiksjlqiie(wcqjuomjxj) = lrjhaszyed caitfydsju (uozzwbvhzn, 19.4 - 40.4) View more | - | 09 Dec 2023 | |||
Phase 1 | 56 | ldswcaugyf(tjlakarwzo) = lpucyvufxe fdasxvgerf (uxbyrxbzkc, 2.7 - NE) View more | - | 08 Jun 2023 | |||
Phase 2 | 40 | kuakfhhehp(rvtrkapkmq) = cgqrrrssuu ntzcvdhnle (fstnogsgac, 11.9 - 54.3) View more | Positive | 31 May 2023 | |||
Phase 1 | 54 | (DLBCL) | zwvkypxqgr(tgvuxlzcbz) = rmfpdlauhb qnyjeufgez (rnsjcsffrc, 0.5 - 7.0) View more | Positive | 15 Nov 2022 | ||
(MCL) | zwvkypxqgr(tgvuxlzcbz) = unwslfitrp qnyjeufgez (rnsjcsffrc, 4.0 - NE) View more | ||||||
Phase 1 | 51 | eqyzgsihen(hlbofmaqvd) = qqyrwsazno irbjyubqyc (ocowekedfi ) View more | Positive | 05 Nov 2021 |